President Barack Obama’s push to deter U.S. firms from buying foreign companies for tax purposes will make several deals less attractive.» Read More
*Astrazeneca rejects Pfizer's raised bid of $106 bln. NEW YORK, May 2- U.S. stock index futures were little changed Friday on caution ahead of the key U.S. nonfarm payrolls report for April.
Some of the names on the move ahead of the open.
*AstraZeneca board rejects sweetened 50 stg/ shr offer. LONDON, May 2- U.S. drugmaker Pfizer Inc increased its offer for AstraZeneca Plc to 63 billion pounds on Friday, but the British company promptly rejected the proposal, which would create the world's biggest pharmaceuticals company.
*Deutsche Telekom rises on T-Mobile US bid speculation. The euro zone's blue-chip Euro STOXX 50 index dipped 0.3 percent to 3,187.72 points. Both the FTSEurofirst 300 and the Euro STOXX 50 have gained more than 2 percent since the start of 2014..
*AstraZeneca board rejects sweetened 50 stg/ shr offer. LONDON, May 2- U.S. drugmaker Pfizer Inc raised its offer for AstraZeneca Plc to 63 billion pounds on Friday, but the British company promptly rejected the proposal, which would create the world's biggest pharmaceuticals company.
LONDON, May 2- AstraZeneca's board said on Friday it had rejected an improved $106 billion takeover offer from U.S. drugmaker Pfizer, saying the bid which was announced just hours ago undervalued the firm.
LONDON, May 2- Global markets traded cautiously on Friday as uncertainty ahead of U.S. employment figures and tensions in Ukraine pushed the yield on 10- year German Bunds to their lowest in a year. That, and an escalation in violence in eastern Ukraine between government forces and pro-Russian separatists, weighed on investor sentiment.
*Dt Telekom rises on T-Mobile US bid speculation. The euro zone's blue-chip Euro STOXX 50 index dipped 0.3 percent to 3,188.48 points. On Friday, Deutsche Telekom rose 1.9 percent, after Reuters reported that U.S. rival Sprint had met with banks ahead of a planned bid for T-Mobile US, which is 67 percent owned by Deutsche Telekom.
LONDON, May 2- The British government said it had pressed U.S. company Pfizer to commit to British jobs and research in its bid for AstraZeneca, but the decision on whether the British group will be sold was a matter for its shareholders.
LONDON, May 2- Shares in Astrazeneca rose 0.4 percent to 48.31 pounds in early trading on Friday after Pfizer raised its offer for the British company to 50.00 pounds per share.
LONDON, May 2- AstraZeneca's board will be reviewing a sweetened takeover offer from Pfizer but the company has no further comment at this stage, a spokeswoman for the British drugmaker said on Friday.
LONDON, May 2- U.S. drugmaker Pfizer has raised its offer for AstraZeneca to 63 billion pounds, it said on Friday, adding that the British drugmaker was reviewing the proposal.
LONDON, May 2- U.S. pharmaceutical group Pfizer Inc has told Prime Minister David Cameron it will retain British jobs and a planned scientific research hub in Cambridge if it succeeds in its bid to take over rival AstraZeneca.
LONDON, May 2- U.S. drugmaker Pfizer said on Friday it had raised its offer for AstraZeneca to 50 pounds a share, adding that the British drugmaker was reviewing the proposal.
Pfizer is set to sweeten its bid for British pharma AstraZeneca. CNBC's Catherine Boyle reports on the developments.
May 1- Pfizer Inc and AstraZeneca Plc have resumed talks about a trans-Atlantic merger of the two drug giants after Pfizer sweetened the terms of an earlier takeover offer for its British rival, the Wall Street Journal reported, citing people familiar with the matter.
CAMBRIDGE, England, May 1- In Pfizer's $100 billion battle to win British drugmaker AstraZeneca, business and politics meet in a grassy field on the edge of the historic university city of Cambridge.
Pfizer CEO Ian Read recently met with U.K.-based investors to discuss a second bid for AstraZeneca, valuing the firm at $106 billion, sources said.
May 1- Pfizer Inc may sweeten its offer for Britain's AstraZeneca Plc to more than 63 billion pounds, or $106 billion, and raise the cash portion of the deal, to kickstart negotiations, Bloomberg reported on Thursday.
LONDON, May 1- Pfizer's plan to buy AstraZeneca for around $100 billion could face antitrust hurdles in China, where the two companies rank No. 1 and No. 2 among multinational suppliers in the prescription drug market.